Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed later-stage tilt small index

Atypical Ductal Breast Hyperplasia: later-stage trial registry

A small indexed set (1 trial) with no open enrollment listed right now.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · none currently recruiting · #11,370 of 28,707 conditions by registered trial count

Atypical Ductal Breast Hyperplasia: 1 US clinical trial tracked, none currently recruiting.

Atypical Ductal Breast Hyperplasia is the subject of 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Alliance for Clinical Trials in Oncology, running 1 of these trials.

Enrollment posture brief

Registry condition atypical-ductal-breast-hyperplasia

OPEN 0 | RECR 0% | LATE 1 | EARLY 0 | RANK #11370 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Atypical Ductal Breast H (th…0%
Open-enrollment share among volume-matched conditions near Atypical Ductal Breast Hyperplasia

Atypical Ductal Breast Hyperplasia has no open enrollment in this registry pull (1 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Atypical Ductal Breast Hyperplasia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Atypical Ductal Breast Hyperplasia is recruiting below its size-band peers.

    0 of 1 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 31

Phase Distribution

PhaseTrial count
Phase 3 1

Named interventions

Most-linked intervention names on Atypical Ductal Breast Hyperplasia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

metformin hydrochloride Drug
1 trials
placebo Other
1 trials

US sites by state

Facility locations filed on Atypical Ductal Breast Hyperplasia trials. A trial with sites in several states counts in each.

South Carolina 1 trials
Oklahoma 1 trials
Ohio 1 trials
New York 1 trials
North Carolina 1 trials
Minnesota 1 trials
Kansas 1 trials
Indiana 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Atypical Ductal Breast Hyperplasia page

1 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No Atypical Ductal Breast Hyperplasia trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Alliance for Clinical Trials in Oncology sponsors the most Atypical Ductal Breast Hyperplasia trials on record, review their full trial history before evaluating a specific study. See Alliance for Clinical Trials in Oncology's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Atypical Ductal Breast Hyperplasia condition card totals 1 registered trials; most-linked intervention metformin hydrochloride; top US site state South Carolina. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.